On December 2, 2015, the National Agency for the Safety of Medicines and Health Products (ANSM) took a health policy decision (DPS) against the company Stallergenes Greer SAS. The agency has imposed a suspension of its activity until compliance is restored. This laboratory specializing in the diagnosis and treatment ofallergy had to recall allergen immunotherapy products. “We have seen growing concern. We therefore wanted to answer patients’ questions“, explained Tuesday an ANSM spokesperson. This is why a toll-free number has been set up for the patients concerned.
Activated since December 21, the 0 800 130,000 allows the patients concerned to find out about the possible risks and the steps to follow following the suspension of the sale of all the laboratory’s allergen immunotherapy products.
But, “Stallergenes desensitization products are part of a long-term treatment, for an effect expected in the more or less long term. Also, the temporary cessation of this type of desensitization treatment does not pose any particular difficulty for the health of the patients. Also, the initiation of such treatment can be postponed because there is never an emergency” recalls the ASNM in a press release.
If in doubt
“A letter has been sent to all patients who have received APSIs since August 13, 2015, asking them to stop the current treatment, return their medication to Stallergenes (in a postage-paid envelope) and contact their doctor. having initiated their allergen immunotherapy treatment in order to adapt their therapeutic management methods” informed the laboratory .
To manage these withdrawals, Stallergenes has set up two toll-free numbers:
One for doctors: 0 800 940 377
The other for patients: 0 800 940 390
Source: Press release from the National Agency for the Safety of Medicines and Health Products (ANSM).
Read also:
The different faces of allergy
Allergy: can you live with a pet?
Allergies and intolerances: what’s the difference?
